This site is intended for health professionals only
Saturday 26 May 2018
Share |

Topic: Latest News

May 24, 2018
European programme to help people access edaravone for ALS treatment established by pharmaceutical companies

Global pharmaceutical organisations have joined forces to improve access to a treatment for amyotrophic lateral sclerosis (ALS).

Clinigen Group plc has partnered with Mitsubishi Tanabe Pharma Corporation (MTPC) in Europe to initiate a ‘Managed Access Program’ for Edaravone, an intravenous treatment for ALS. The initiative is also known as ‘Early Access Program’.

Edaravone has been approved for use as a treatment for ALS in Japan, South Korea and the USA.

May 24, 2018
Children and adults treated with some oral antibiotics have a significantly higher risk of developing kidney stones, paediatric researchers have found

Children and adults treated with some oral antibiotics have a higher risk of developing kidney stones, paediatric researchers have suggested.

Researchers said this is the first time these medicines have been linked to this condition. The strongest risks appeared at younger ages, and also among patients most recently exposed to antibiotics.

May 24, 2018
Juluca (dolutegravir/rilpivirine), has been endorsed as the first 2-drug regimen, once-daily, single-pill for the treatment of HIV

The first two-drug regimen to treat some patients with HIV in Europe has been approved ViiV Healthcare and Janssen have announced.

Juluca consists of ViiV’s dolutegravir, which is an integrase strand transfer inhibitor, and Janssen’s rilpivirine 25mg, a non-nucleoside reverse transcriptase inhibitor.

May 22, 2018
The study analysed data from more than 421,000 people aged 60–69 in both GP medical records and in the UK Biobank research study. Participants were followed up over ten years.

New research has shown that older people with very low heart disease risks also have very little frailty, raising the possibility that frailty could be prevented.

The largest study of its kind, led by the University of Exeter, found that even small reductions in risk factors helped to reduce frailty, as well as dementia, chronic pain, and other disabling conditions of old age.

May 18, 2018
New indication supports Amgen’s commitment to reduce the risk of recurrent cardiovascular events faced by heart attack and stroke survivors

Amgen has announced announced that the European Commission (EC) has approved a new indication in the Repatha® (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) levels.

May 18, 2018
Green light for advanced bladder cancer patients whose disease has progressed following chemotherapy

Patients with advanced bladder cancer whose disease has progressed during or after treatment with platinum-containing chemotherapy, can now access the new immunotherapy Tecentriq (atezolizumab) via routine NHS funding in England and Wales.1

May 18, 2018
Nearly half of women with HIV lack help to manage menopause, a new study finds

Women with HIV are failing to get the support they need during menopause, according to a study led by University College London (UCL).

The PRIME (Positive Transitions through the Menopause) report involved almost 900 women living with HIV aged 45-60 across England, who completed questionnaires and interviews between June 2015 and April 2018. Researchers found that 47% of women with HIV do not have the information they need to manage menopause.

May 17, 2018
Public health scheme aims to improve awareness of atopic dermatitis

A scheme to raise awareness about the emotional and physical impact of the most common type of eczema has been launched by a leading charity and a global biopharmaceutical company this month.

May 17, 2018
Every year there are estimated to be over 100,000 strokes in the UK, including over 20,000 in patients with ‘wake-up stroke’ or who otherwise have an unknown time of symptom onset

Detail revealed in MRI brain scans can help doctors accurately deduce when a stroke begins, according to new research, allowing treatment for many patients who currently cannot receive it.

The findings could help to better treat stroke patients, particularly those who wake up with stroke symptoms. Currently, those patients who do not know when their stroke began are not routinely eligible for clot-busting treatment, which is only able to be used a few hours after stroke symptoms start.

May 17, 2018
NICE U-turn recommends Biogen’s Avonex® (interferon beta-1a) for relapsing-remitting multiple sclerosis

The National Institute for Health and Care Excellence (NICE) has recommended global biotechnology  company Biogen’s Avonex® (interferon beta-1a) as an option for treating relapsing-remitting multiple sclerosis.

The reappraisal of the treatment comes after the landmark Risk Sharing Scheme ended, at which point NICE began an appraisal of treatments including interferon beta-1a, Extavia (interferon beta-1b), glatiramer acetate and Betaferon (interferon beta-1b).

May 11, 2018
Scottish Medicines Consortium gives positive decision for Stivarga® (regorafenib) for treatment of adults with hepatocellular carcinoma who have been previously treated with sorafenib

Stivarga® (regorafenib) has been accepted by the Scottish Medicines Consortium (SMC) as a monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar® (sorafenib).1

Regorafenib is the first medicine to be specifically licensed for second-line use in patients with HCC who had formerly been treated with sorafenib, the German multinational pharmaceutical company Bayer has announced.

May 11, 2018
NHS failure to send invitations may have resulted in women having their lives shortened, according to estimates

Nearly half a million women in England have missed out on a routine breast screening appointment due to an NHS failure to send invitations. 

Up to 270 women may have had their lives shortened as a result, according to estimates. A computer error has been blamed for the missed invitations.

May 10, 2018
Both studies investigated links between postoperative delirium and particular biomarkers

Masimo has announced the use of Masimo technologies – O3® regional oximetry and SedLine® brain function monitoring – in two abstracts presented at the 2018 Annual Meeting of the International Anesthesia Research Society (IARS). Both studies investigated links between postoperative delirium and particular biomarkers.

May 10, 2018
Blood cancer drugs brentuximab, vedotin, midostaurin will now be available on the NHS giving hundreds of individuals more therapy choices

The National Institute for Health and Care Excellence (NICE) has recommended three blood cancer drugs, brentuximab vedotin, midostaurin and arsenic trioxide be made available on the NHS.

Two of the therapies, midostaurin, also known as the Novartis drug Rydapt, and arsenic trioxide, Teva’s Trisenox, are recommended for adults with certain types of leukaemia.

May 10, 2018
Researchers investigated the utility of Masimo non-invasive and continuous haemoglobin in supporting and enhancing red blood cell transfusion best practices as part of post-operative patient blood management

Masimo has announced the findings of an abstract presented at the 2018 Annual Meeting of the Network for the Advancement of Patient Blood Management, Haemostatis and Thrombosis (NATA), in which researchers investigated the utility of Masimo noninvasive and continuous haemoglobin (SpHb®) in supporting and enhancing red blood cell (RBC) transfusion best practices as part of post-operative patient blood management (PBM).1

May 8, 2018
Roadmap to the EU 28 medical device markets

MedTech data management enabler MEDEI ApS

May 8, 2018
Major study proposes an algorithm that should be used to determine innovative drug prices with ‘a maximum level of transparency’.

A major study published in Nature Reviews states that a global revolution in new cancer drug pricing must occur if the world is to cope with rapidly increasing instances of the disease.

May 4, 2018
Herzuma is the third biosimilar to be marketed and distributed by the Mundipharma network in Europe

The Mundipharma global network of independent associated companies has announced that Herzuma, biosimilar trastuzumab, is now available in Europe, with the product now launched in both the UK and Germany and further launches across European countries anticipated in the coming months.

The Mundipharma network has exclusive distribution rights to Herzuma
in the UK, Germany, Italy, Ireland, Belgium, Luxembourg and the Netherlands.

May 4, 2018
Immune cells are able to fight different strains of the same viruses, which could change the way vaccines are produced and given, a study finds

Immune cells can fight different strains of the same virus, which could help transform vaccine development, researchers have discovered.

Vaccines become ineffective when a virus mutates, and tackling this problem is a priority for researchers. Vaccinations aim to stimulate the body to produce ‘memory’ cells which provide long-lasting protection from disease. It was thought that these cells could only remember – and be able to protect against – one particular strain of virus.

May 4, 2018
The NICE decision will result in quicker access for patients to the first selective IL-23 inhibitor

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the UK’s National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Determination (FAD) recommending Tremfya® (guselkumab) for treatment of adults with moderate to severe plaque psoriasis.1
 
The NICE recommendation states that guselkumab is recommended as an option for treating plaque psoriasis in adults, only if:

May 3, 2018
Study finds the addition of this medicine to lenalidomide and dexamethasone (KRd) can extend the life of people with incurable blood cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a label variation for KYPROLIS® (carfilzomib) to include the final overall survival data, following a recent Phase III trial.

KYPROLIS® is the first and only relapsed or refractory multiple myeloma treatment to demonstrate overall survival (OS) in two Phase III studies, Amgen, the American multi-national biopharmaceutical company, has announced [April 30].

May 3, 2018
Leading cancer charities launch awards to help advance understanding of the disease and develop new treatments to improve survival

Leading cancer charities have established a multi million pound fund to improve the understanding and treatment of brain tumours.

The Cancer Research UK Brain Tumour Awards was launched this month [1 May] by Cancer Research UK in partnership with The Brain Tumour Charity to help advance understanding about the biology of the disease and the challenges translating discoveries into treatments.

Research teams can apply for grants up to £10 million for each project over five years. Up to £18 million will be awarded in the first round.

May 1, 2018
The compact and highly portable ultrasound systems will provide the BSB medical team with on-site imaging capabilities, to support the first-class care of riders and teams competing in the championship

FUJIFILM SonoSite is pleased to be supporting the 2018 Bennetts British Superbike Championship (BSB) by supplying point-of-care ultrasound systems for clinic-based and trackside imaging.

The compact and highly portable ultrasound systems will provide the BSB medical team with on-site imaging capabilities, to support the first-class care of riders and teams competing in the championship.

April 28, 2018
ESMO has shared concerns expressed in a recent paper and reflected in the international media about the rising costs of cancer medicines

ESMO, the leading professional organisation for medical oncology, shares concerns expressed in a scientific paper1 and reflected in the international media about the rising costs of cancer medicines.